DV
Dividend Vision

FLNA — Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (FLNA)

Total return is -99.0% over the past 26.1 years, 814.2 points behind SPY at 715.2%. Its deepest 1-year drawdown was 81.2%.

Filana Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, with its lead candidate simufilam in Phase 3 trials for Alzheimer's disease and an early-stage blood-based diagnostic program called SavaDx. The company does not currently distribute dividends. Filana appeals primarily to investors seeking exposure to clinical-stage biotech development rather than current income.

FLNA key facts

Asset type
Stock
Asset class
Equity
Inception date
07/14/2000
Last close
$0.91
Market cap
$51,206,368
Average volume
291700.0
Ex-dividend date
12/13/2012
Payment date
12/24/2012
Beta
-0.737
Payout ratio
0.0
Forward P/E
151.5152
EPS
$-1.61